Bypassing the blood-brian barrier using established skull base reconstruction techniques

World Journal of Otorhinolaryngology - Head and Neck Surgery

Volumn 1, Issue 1, 2015, Pages 11-16

  Miyake, Marcel M ^a,b,c   Bleier, Benjamin S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Medical School of Santa Casa of Sao Paulo SP   (Brazil)

^c CAPES Brazil Scholarship   (Brazil)

Author keywords

Blood brain barrier; Mucosal flap; Skull base reconstruction; Transnasal drug delivery

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INSULIN; NERVE GROWTH FACTOR;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CRANIOPLASTY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENDOSCOPIC SURGERY; HETEROTOPIC MUCOSAL GRAFT; HUMAN; INSULIN BLOOD LEVEL; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NASOSEPTAL FLAP RECONSTRUCTION; NERVE FIBER TRANSPORT; NEUROLOGIC DISEASE; NEUROLOGICAL CATHETER; NONHUMAN; PARKINSON DISEASE; REVIEW; SAFETY; SURGICAL TECHNIQUE;

EID: 84981181902     PISSN: 20958811     EISSN: 25891081     Source Type: Journal    
DOI: 10.1016/j.wjorl.2015.09.001     Document Type: Review

References (47)

1. World Health Organization. Neurological disorders: public health challenges. Available at: . http://www.who.int/mental_health/neurology/neurodiso/en/index.html.
2. Wimo A., Prince M. World Alzheimer Report 2010 2010, Alzheimer's Disease International, London, UK, Sci Rep.
3. Parkinson's Disease: Hope through Research 2006, National Institute of Neurologic Disorders and Stroke, Bethesda, MD, Sci Rep.
4. Huse D.M., Schulman K., Orsini L., Castelli-Haley J., Kennedy S., Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005, 20:1449-1454. 10.1002/mds.20609.
5. De Lau L.M.L., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535. 10.1016/S1474-4422(06)70471-9.
6. Ngwuluka N., Pillay V., Du Toit L.C., et al. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin Drug Deliv 2010, 7:203-224. 10.1517/17425240903483166.
7. Cardoso F.L., Brites D., Brito M.A. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 2010, 64:328-363. 10.1016/j.brainresrev.2010.05.003.
8. Goldmann E. Vitalfarbung am zentralnervensystem. Abhandl Konigl Preuss Akad Wiss 1913, 1:1-60.
9. Abbott N.J., Dolman D.E., Patabendige A.K. Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr Drug Metab 2008, 9:901-910.
10. Hawkins B.T., Egleton R.D. Pathophysiology of the blood-brain barrier: animal models and methods. Curr Top Dev Biol 2008, 80:277-309. 10.1016/S0070-2153(07)80007-X.
11. Chen Y., Dalwadi G., Benson H.A. Drug delivery across the blood-brain barrier. Curr Drug Deliv 2004, 1:361-376.
12. McGlinchey R.P., Lee J.C. Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease. Biochem Soc Trans 2013, 41:1509-1512. 10.1042/BST20130158.
13. Shimamura T., Husain S.R., Puri R.K. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg Focus 2006, 20:E11. 10.3171/foc.2006.20.4.6.
14. Wang D., El-Amouri S.S., Dai M., et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci U. S. A 2013, 110:2999-3004. 10.1073/pnas.1222742110.
15. Kohli N., Westerveld D.R., Ayache A.C., et al. Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers. Mol Ther 2013, 10.1038/mt.2013.273.
16. Zhang Y., Pardridge W.M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 2005, 313:1075-1081. 10.1124/jpet.104.082974.
17. Dietz G.P., Valbuena P.C., Dietz B., et al. Application of a blood - brain-barrier-penetrating form of GDNF in a mouse model for Parkinson' s disease. Brain Res 2006, 1082:61-66.
18. Kroll R.A., Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083-1099. discussion 1099-1100.
19. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220:640-646. 10.1148/radiol.2202001804.
20. Shashoua V.E., Hesse G.W. N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci 1996, 58:1347-1357. 10.1016/0024-3205(96)00101-4.
21. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14. 10.1602/neurorx.2.1.3.
22. Boado R.J. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 2007, 24:1772-1787. 10.1007/s11095-007-9321-5.
23. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57. 10.1016/j.nbd.2009.07.028.
24. Stockwell J., Abdi N., Lu X., Maheshwari O., Taghibiglou C. Novel Central nervous system drug delivery systems. Chem Biol Drug Des 2013, 10.1111/cbdd.12268.
25. Jarry U., Donnou S., Vincent M., et al. Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection. J Neuroimmunol 2013, 10.1016/j.jneuroim.2013.12.005.
26. Gill S.S., Patel N.K., Hotton G.R., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595. 10.1038/nm850.
27. Hanson L.R., Frey W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008, 9(suppl 3):S5. 10.1186/1471-2202-9-S3-S5.
28. Fisher A.N., Illum L., Davis S.S., Schacht E.H. Di-iodo-l-tyrosine-labelled dextrans as molecular size markers of nasal absorption in the rat. J Pharm Pharmacol 1992, 44:550-554.
29. De Rosa R., Garcia A.A., Braschi C., et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U. S. A 2005, 102:3811-3816. 10.1073/pnas.0500195102.
30. Reger M.A., Watson G.S., Frey W.H., et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006, 27:451-458. 10.1016/j.neurobiolaging.2005.03.016.
31. In't Veen J.P.M., van den Berg M.P., Romeijn S.G., Verhoef J.C., Merkus F.W.H.M. Uptake of fluorescein isothiocyanate-labelled dextran into the CSF after intranasal and intravenous administration to rats. Eur J Pharm Biopharm 2005, 61:27-31. 10.1016/j.ejpb.2005.02.015.
32. Shingaki T., Hidalgo I.J., Furubayashi T., et al. The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). Int J Pharm 2009, 377:85-91. 10.1016/j.ijpharm.2009.05.009.
33. Shimizu H., Oh-I S., Okada S., Mori M. Inhibition of appetite by nasal leptin administration in rats. Int J Obes (Lond) 2005, 29:858-863. 10.1038/sj.ijo.0802951.
34. Holbrook E.H., Wu E., Curry W.T., Lin D.T., Schwob J.E. Immunohistochemical characterization of human olfactory tissue. Laryngoscope 2011, 121:1687-1701. 10.1002/lary.21856.
35. Bleier B.S., Debnath I., Harvey R.J., Schlosser R.J. Temporospatial quantification of fluorescein-labeled sinonasal irrigation delivery. Int Forum Allergy Rhinol 2011, 1:361-365. 10.1002/alr.20041.
36. Gudis D., Zhao K., Cohen N.A. Acquired cilia dysfunction in chronic rhinosinusitis. Am J Rhinol Allergy 2012, 26:1-6. 10.2500/ajra.2012.26.3716.
37. Merkus F.W., van den Berg M.P. Can nasal drug delivery bypass the blood-brain barrier?. Drugs R D 2007, 8:133-144. 10.2165/00126839-200708030-00001.
38. Bleier B.S., Palmer J.N. Cranial-base repair using endoscopic laser welding. Otolaryngol Clin North Am 2009, 42:901-906. xi. 10.1016/j.otc.2009.07.002.
39. White D.R., Dubin M.G., Senior B.A. Endoscopic repair of cerebrospinal fluid leaks after neurosurgical procedures. Am J Otolaryngol 2003, 24:213-216.
40. Cassano M., Felippu A. Endoscopic treatment of cerebrospinal fluid leaks with the use of lower turbinate grafts: a retrospective review of 125 cases. Rhinology 2009, 47:362-368. 10.4193/Rhin08.175.
41. Kimple A.J., Leight W.D., Wheless S.A., Zanation A.M. Reducing nasal morbidity after skull base reconstruction with the nasoseptal flap: free middle turbinate mucosal grafts. Laryngoscope 2012, 122:1920-1924. 10.1002/lary.23325.
42. Hadad G., Bassagasteguy L., Carrau R.L., et al. A novel reconstructive technique after endoscopic expanded endonasal approaches: vascular pedicle nasoseptal flap. Laryngoscope 2006, 116:1882-1886. 10.1097/01.mlg.0000234933.37779.e4.
43. Bleier B.S., Wang E.W., Vandergrift W.A., Schlosser R.J. Mucocele rate after endoscopic skull base reconstruction using vascularized pedicled flaps. Am J Rhinol Allergy 2011, 25:186-187. 10.2500/ajra.2011.25.3587.
44. Harvey R.J., Parmar P., Sacks R., Zanation A.M. Endoscopic skull base reconstruction of large dural defects: a systematic review of published evidence. Laryngoscope 2012, 122:452-459. 10.1002/lary.22475.
45. Chaaban M.R., Woodworth B.A. Complications of skull base reconstruction. Adv Otorhinolaryngol 2013, 74:148-162. 10.1159/000342291.
46. Bleier B.S., Kohman R.E., Feldman R.E., Ramanlal S., Han X. Permeabilization of the blood-brain barrier via mucosal Engrafting: Implications for drug delivery to the brain 2013, 8:1-7. 10.1371/journal.pone.0061694.
47. Lam C.H., Hansen E.A., Hall W.A., Hubel A. Application of transport phenomena analysis technique to cerebrospinal fluid. J Neurosurg Sci 2013, 57:317-326.